Cosmo Pharmaceuticals NV (CHIX:COPNZ) Total Assets : CHF718.8 Mil (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Cosmo Pharmaceuticals NV Total Assets?

Cosmo Pharmaceuticals NV's Total Assets for the quarter that ended in Jun. 2023 was CHF718.8 Mil.

During the past 12 months, Cosmo Pharmaceuticals NV's average Total Assets Growth Rate was -10.40% per year. During the past 3 years, the average Total Assets Growth Rate was 13.90% per year. During the past 5 years, the average Total Assets Growth Rate was 11.10% per year. During the past 10 years, the average Total Assets Growth Rate was 15.60% per year.

During the past 13 years, Cosmo Pharmaceuticals NV's highest 3-Year average Total Assets Growth Rate was 48.20%. The lowest was -3.70%. And the median was 18.35%.

Total Assets is connected with ROA %. Cosmo Pharmaceuticals NV's annualized ROA % for the quarter that ended in Jun. 2023 was 0.39%. Total Assets is also linked to Revenue through Asset Turnover. Cosmo Pharmaceuticals NV's Asset Turnover for the quarter that ended in Jun. 2023 was 0.06.

Cosmo Pharmaceuticals NV Total Assets Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Total Assets Chart

Cosmo Pharmaceuticals NV Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Assets

Get a 7-Day Free Trial

706.05

638.87

644.32

838.33

749.61

Cosmo Pharmaceuticals NV Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Assets	Get a 7-Day Free Trial															615.51	838.33	784.83	749.61	718.78

Cosmo Pharmaceuticals NV Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Cosmo Pharmaceuticals NV's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	457.696	+	291.918
	=	749.6

Cosmo Pharmaceuticals NV's Total Assets for the quarter that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2023 )	+	Total Liabilities (Q: Jun. 2023 )
	=	427.431	+	291.345
	=	718.8

Cosmo Pharmaceuticals NV (CHIX:COPNz) Total Assets Explanation

Total Assets is connected with ROA %.

Cosmo Pharmaceuticals NV's annualized ROA % for the quarter that ended in Jun. 2023 is

ROA %	=	Net Income (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	2.9	/	( (749.614	+	718.776)	/ 2 )
	=	2.9	/	734.195
	=	0.39 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Cosmo Pharmaceuticals NV's Asset Turnover for the quarter that ended in Jun. 2023 is

	Asset Turnover
=	Revenue (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
=	42.592	/	( (749.614	+	718.776)	/ 2 )
=	42.592	/	734.195
=	0.06

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Cosmo Pharmaceuticals NV Total Assets Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (CHIX:COPNz) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

CMOPF:USA C43:Germany COPN:Switzerland

Address

Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2

Website

https://www.cosmopharma.com

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Headlines

No Headlines